T1	p 81 130	children and adolescents with autistic disorder .
T2	p 282 332	children and adolescents with autistic disorders .
T3	p 349 511	6 month ( 26 week ) open-label extension ( OLE ) study , patients ( 5-17 years of age , who completed the previous fixed-dose , 6 week , double-blind [ DB ] phase
T4	p 805 871	Fifty-six ( 71 % ) out of 79 enrolled patients completed the OLE ;
T5	i 66 77	risperidone
T6	i 220 231	risperidone
T7	i 392 395	OLE
T8	i 539 550	risperidone
T9	i 724 735	risperidone
T10	i 1584 1595	risperidone
T11	i 1820 1841	risperidone treatment
T12	i 2000 2011	risperidone
T13	o 197 216	safety and efficacy
T14	o 244 256	irritability
T15	o 736 756	's safety ; efficacy
T16	o 950 974	or adverse events ( AE )
T17	o 1044 1049	) AEs
T18	o 1055 1073	increased appetite
T19	o 1093 1124	increased weight and vomiting (
T20	o 1146 1204	sedation , pyrexia , and upper respiratory tract infection
T21	o 1228 1243	nasopharyngitis
T22	o 1266 1288	somnolence and fatigue
T23	o 1312 1330	Extrapyramidal AEs
T24	o 1381 1394	mean weight (
T25	o 1403 1424	) and body mass index
T26	o 1483 1564	weight increase . One potentially prolactin-related AE ( irregular menstruation )
T27	o 1629 1674	mean improvement in sleep visual analog scale
T28	o 1715 1751	improvement in efficacy scale scores
T29	o 1977 1983	safety
T30	o 2119 2153	irritability and related behaviors